-
Ladenburg Thalmann On Biotech: Buy BioCryst, Albireo Shares
Thursday, February 16, 2017 - 12:27pm | 474Read More...Biotechnology stocks have experienced high price and volume fluctuations that “have often been unrelated or disproportionate to the operating performance of companies, ” according to Ladenburg Thalmann analysts. Against this backdrop, Ladenburg Thalmann initiated coverage of two biotech...
-
Ladenburg On Biotech: Starts Achillion, Alnylam, Corcept, Trevana At Buy
Thursday, February 2, 2017 - 10:21am | 701Read More...Ladenburg Thalmann’s Christopher S. James initiated coverage of four biotech companies with a Buy rating, given that each has a promising lead drug candidate that is expected to drive growth in the near future. Achillion Pharmaceuticals James initiated coverage of Achillion Pharmaceuticals,...
-
FBR Upgrades Keryx Biopharma To Outperform, Sees Meaningful Auryxia Sales & Potential Label Expansion
Monday, February 29, 2016 - 8:53am | 182Read More...FBR’s Christopher S. James upgraded the rating for Keryx Biopharmaceuticals (NASDAQ: KERX) from Market Perform to Outperform, with a price target of $10. The company reported a higher-than-expected 4Q loss per share of $0.36, due to interest expenses related to the amortization of...
-
McNicoll, Lewis & Vlak LLC Maintains Buy Rating On XOMA Limited (XOMA)
Wednesday, April 14, 2010 - 11:48am | 78Read More...Analyst Christopher S. James at McNicoll, Lewis & Vlak LLC has released an update on XOMA Limited (NASDAQ: XOMA). On Tuesday, the company announced the issuance of two U.S. patents for XOMA 052. The research firm believes that these U.S. patents serve greatly to enhance the value of XOMA 052,...
